Drug
Lutetium Lu 177 Zadavotide Guraxetan clinical trials
Also written [177Lu]Lu-PSMA I&T and 177Lu-PNT2002.
Keep track of what changes. Save the Lutetium Lu 177 Zadavotide Guraxetan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 7
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (2) · Medical University of Vienna (2) · Jonsson Comprehensive Cancer Center (1) · Glenn Bauman (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Studies
Open first, then newest update. How each study uses Lutetium Lu 177 Zadavotide Guraxetan is read from its arms, and is right about nine times in ten.
Testing it · 7
- Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)RecruitingPhase 2Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT05893381Written as [177Lu]Lu-PSMA I&T
- Neoadjuvant PSMA-RLT in Oligometastatic PCaRecruitingPhase 2Medical University of ViennaNCT06259123Written as [177Lu]Lu-PSMA I&T
- PSMA-RLT in Biochemically Recurrent PCaRecruitingPhase 2Medical University of ViennaNCT06220188Written as [177Lu]Lu-PSMA I&T
- 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR StudyActive, not recruitingPhase 2Jonsson Comprehensive Cancer CenterNCT05496959Written as Lutetium Lu-177 PNT2002
- 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic CarcinomaTerminatedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06322576Written as 177Lu-PNT2002
- Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:Active, not recruitingPhase 2Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT05867615Written as [177Lu]Lu-PSMA I&T
- Radioligand fOr locAl raDiorecurrent proStaTe cancERCompletedPhase 1/2Glenn BaumanNCT05230251Written as 177Lu-PNT2002
Given in every arm · 2 — Lutetium Lu 177 Zadavotide Guraxetan is usual care beside what is tested
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentActive, not recruitingPhase 3POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyNCT04647526Written as [Lu-177]-PNT2002
- PSMA Therapy and Immunotherapy in Kidney CancerWithdrawnPhase 1/2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06361810Written as 177Lu-PNT2002
Codes
What other systems call Lutetium Lu 177 Zadavotide Guraxetan · ClinicalTrials.gg INT016632
- UNII (FDA) G5B860B0G1LUTETIUM LU-177 ZADAVOTIDE GURAXETANOne source FDA
- NCI Thesaurus C184831Lutetium Lu 177 Zadavotide GuraxetanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | G5B860B0G1 | LUTETIUM LU-177 ZADAVOTIDE GURAXETAN | One source FDA |
| NCI Thesaurus | C184831 | Lutetium Lu 177 Zadavotide Guraxetan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.